|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of lamivudinein in BeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level显示文摘AIM: To clarify differences in antiviral effect of the drug in patients with different ALT levels, we examined the changes in HBV markers in patients with high or low ALT levels with or without lamivudine treatment. METHODS: Thirty-seven HBeAg-positive patients were studied. Ten patients with ALT levels higher than 200 IU/L (group 1) and 8 patients with ALT below 200 IU/L (group 2) were treated orally with 100 mg/d of lamivudine. As untreated control, 9 patients with ALT above 200 IU/L (group 3) and 10 patients with ALT below 200 IU/L (group 4) were examined. ALT level, HBeAg/HBeAb status, and HBV DNA level were examined monthly for 11.9±0.4 mo.RESULTS: The ALT level normalized in all 10 patients of group 1, 7/8 of group 2, 4/9 of group 3, and 1/10 of group 4 within 6 mo (groups 1 vs 2, P = NS; groups 1 vs 3, P = 0.002; groups 1vs 4, P<0.0001). HBV DNA fell below the detection limit in all 10 patients of group 1, 7/8 of group 2, 0/9 of group 3, and 0/10 of group 4 within 6 mo (groups 1 vs 2, P = NS). HBeAg became seronegative in 7/10 patients of group 1, 1/8 of group 2, 3/9 of group 3, and 0/10 of group 4 within 12 mo (groups 1 vs2, P= 0.02;groups 1 vs 3, P = NS).CONCLUSION: Our data suggest that HBeAg-positive patients with higher ALT levels can be considered good candidates for lamivudine therapy, probably because lamivudine accelerates the natural seroconversion of HBeAg, accompanied by HBV DNA loss, in these patients. | Tomoko Kurihara Fumio Imazeki Osamu Yokosuka Kenichi Fukai Tatsuo Kanda Shigenobu Kawai Hiromitsu Saisho | 2005 | World Journal of Gastroenterology2005，11，22： | 5 |
| 2 | Sofosbuvir treatment and hepatitis C virus infection显示文摘Hepatitis C virus(HCV) infection is a serious problem worldwide.The use of interferon-based therapy has made HCV eradication challenging.The recent appearance of direct-acting antiviral agents(DAAs) has changed HCV therapy.Combining the use of DAAs with peginterferon and ribavirin has improved treatment efficacy.Furthermore,the combination of different orally administered DAAs has enabled interferon-free therapy with much higher efficacy and safety.In particular,sofosbuvir,a nucleotide-based NS5 B inhibitor,prevents HCV RNA synthesis by acting as a 'chain terminator'.Treatment with sofosbuvir has attained an extremely high rate of sustained virologic response.The current review summarizes the efficacy and safety of sofosbuvir therapy. | Masato Nakamura Tatsuo Kanda Yuki Haga Reina Sasaki Shuang Wu Shingo Nakamoto Shin Yasui Makoto Arai Fumio Imazeki Osamu Yokosuka | 2016 | World Journal of Hepatology2016，8，3： | 4 |
| 3 | 在有阴暗胃肠的流血的病人的囊内视镜检查法的计算图象修正的功效显示文摘 AIM:To investigate whether flexible spectral color enhancement(FICE) improves diagnostic yields of capsule endoscopy(CE) for obscure gastro-intestinal bleeding(OGIB).METHODS:The study subjects consisted of 81 patients.Using FICE,there were three different sets with different wavelengths.Using randomly selected sets of FICE,images of CE were evaluated again by two individuals who were not shown the conventional CE reports and findings.The difference between FICE and conventional imaging was examined.RESULTS:The overall diagnostic yields in FICE sets 1,2,3 and conventional imaging(48.1%) were 51.9%,40.7%,51.9% and 48.1%,respectively,which showed no statistical difference compared to conventional imaging.The total numbers of detected lesions per examination in FICE imaging and conventional imaging were 2.5 ± 2.1 and 1.8 ± 1.7,respectively,which showed a significant difference(P = 0.01).CONCLUSION:The diagnostic yield for OGIB is not improved by FICE.However,FICE can detect significantly more small bowel lesions compared to conventional imaging. | Tomoaki Matsumura Makoto Arai Toru Sato Tomoo Nakagawa Daisuke Maruoka Masaru Tsuboi Sachio Hata Eiji Arai Tatsuro Katsuno Fumio Imazeki Osamu Yokosuka | 2012 | World Journal of Gastrointestinal Endoscopy2012，4，9： | 4 |
| 4 | New antiviral therapies for chronic hepatitis C显示文摘 | Tatsuo Kanda Fumio Imazeki Osamu Yokosuka | 2010 | Hepatology International2010，，3： | 4 |
| 5 | Pulmonary artery sarcoma successfully treated by right pneumonectomy after definitive diagnosis显示文摘Pulmonary artery sarcoma(PAS)is a rare and lethal neoplasm that is usually diagnosed during surgery or autopsy.Early diagnosis and radical surgical resection offer the only chance for survival.However,making a preoperative histopathological diagnosis is quite difficult.We encountered a 57-year-old woman presenting a PAS that mimicked a pulmonary thromboembolism.After confirming a definitive diagnosis using a catheter suction biopsy,we successfully performed a right pneumonectomy via a median sternotomy without cardiopulmonary bypass.Eighteen months after surgery,no recurrence was observed. | Ryuta Fukai Kyu Rokkaku Yoshihito Irie Takao Imazeki Yoshiaki Katada Hiroyoshi Watanabe Yoshihiko Ueda Hideaki Miyamoto Masayuki Chida | 2013 | World Journal of Clinical Oncology2013，4，4： | 4 |
| 6 | Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review显示文摘Direct-acting antiviral agents(DAAs)for hepatitis C virus(HCV)infection are one of the major advances in its medical treatment.The HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States,Europe,and Japan.When combined with peginterferon plus ribavirin,these agents increase sustained virologic response rates to70%-80%in treatment-na?ve patients and previoustreatment relapsers with chronic HCV genotype 1 infection.Without peginterferon plus ribavirin,DAA monotherapies increased DAA-resistance mutations.Several new DAAs for HCV are now in clinical development and are likely to be approved in the near future.However,it has been reported that the use of these drugs also led to the emergence of DAA-resistance mutations in certain cases.Furthermore,these mutations exhibit cross-resistance to multiple drugs.The prevalence of DAA-resistance mutations in HCV-infected patients who were not treated with DAAs is unknown,and it is as yet uncertain whether such variants are sensitive to DAAs.We performed a population sequence analysis to assess the frequency of such variants in the sera of HCV genotype 1-infected patients not treated with HCV protease inhibitors.Here,we reviewed the literature on resistance variants of HCV protease inhibitors in treatment na?ve patients with chronic HCV genotype 1,as well as our experience. | Shuang Wu Tatsuo Kanda Shingo Nakamoto Fumio Imazeki Osamu Yokosuka | 2013 | World Journal of Gastroenterology2013，19，47： | 3 |
| 7 | New antiviral therapies for chronic hepatitis C显示文摘 | Tatsuo Kanda Fumio Imazeki Osamu Yokosuka | 2010 | Hepatology International2010，，3： | 3 |
| 8 | Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman显示文摘A 44-year-old woman developed jaundice and was diagnosed as stage II of primary biliary cirrhosis (PBC). She showed a severely high total cholesterol level. This article focuses on atypical presentations of PBC and the need to test the total cholesterol level of PBC patients. | Tatsuo Kanda Osamu Yokosuka Hiroshige Kojima Fumio Imazeki Keiich Nagao Ichiro Tatsuno Yasushi Saito Hiromitsu Saisho | 2004 | World Journal of Gastroenterology2004，10，17： | 2 |
| 9 | Nuclear receptor mRNA expression by HBV in human hepatoblastoma cell lines显示文摘 | Shuang Wu Tatsuo Kanda Fumio Imazeki Shingo Nakamoto Hiroshi Shirasawa Osamu Yokosuka | 2011 | Cancer Letters2011，，1： | 2 |
| 10 | 在有固执地正常的丙氨酸 aminotransferase 的丙肝病毒病人的 IL-28B 多型性和治疗反应显示文摘 AIM:To examine the association between the interleukin 28B(IL-28B)genotype and treatment response in hepatitis C virus(HCV)-infected patients with persistently normal alanine aminotransferase(PNALT).METHODS:We compared the treatment response of HCV-infected patients with PNALT to that of patients with non-PNALT.Between February 2010 and April2013,278 patients infected with HCV were enrolled in this study.All of the patients were treated with peginterferon-alpha 2a or 2b plus ribavirin.In addition,180μg of peginterferon alpha-2a or 1.5μg/kg peginterferon alpha-2b per week plus weight-based ribavirin(600-1000 mg/d)were typically administered for 24 wk to HCV genotype 2-infected patients or for 48-72 wk to HCV genotype 1-infected patients.In all of the patients,the IL-28B rs8099917 genotype was determined using a TaqMan single-nucleotide polymorphism assay.HCV RNA was measured using the COBAS TaqMan HCV test.RESULTS:Female patients were dominant in the PNALT group(P<0.0001).Among 72 HCV genotype 1-infected patients with PNALT,the early virologic response(EVR)rates(P<0.01)and the sustained virologic response(SVR)rates(P<0.01)were higher in patients with the IL-28B TT genotype than in those with the IL-28B TG/GG genotype.In HCV genotype 1-infected patients with PNALT,multivariate logistic-regression analysis showed that SVR was independently predicted by the IL-28B rs8099917 TT type(P<0.05)and having an EVR(P<0.01).The IL-28B rs8099917 TT genotype strongly correlated with treatment response in HCV genotype 1-infected Asian patients with PNALT.CONCLUSION:The IL-28B genotype may be useful for selecting HCV genotype 1-infected patients with PNALT who should receive interferon-based treatment. | Tatsuo Miyamura Tatsuo Kanda Masato Nakamura Xia Jiang Shuang Wu Shingo Nakamoto Shigeru Mikami Nobuo Takada Fumio Imazeki Osamu Yokosuka | 2013 | World Journal of Hepatology2013，5，11： | 2 |
| 11 | Incidence of hepatocellular carcinoma in chronic hepatitis B and C : a prospective study of 251 patients显示文摘 | Takano S Yokosuka O Imazeki F | 1995 | Hepatology1995，21，3： | 1 |
| 12 | Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C:comparison with hepatitis B virus-infected and hepatitis C viruscleared patients显示文摘 | Imazeki F Yokosuka O Fukai K | | 0，，： | 1 |
| 13 | Bezafibrate t reatment:a new medical approach for PBC patients显示文摘 | Kanda T Yokosuka O Imazeki F | 2003 | J Gastroenterol2003，38，6： | 1 |
| 14 | Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues 显示文摘 | Kondoh N Imazeki N Arai M | 2007 | Int J Oncol2007，31，1： | 1 |
| 15 | Immunosteroid as a regulator for Th1/Th2 balance:its possible role in autoimmune diseases 显示文摘 | Matsuzaki J Tsuji T Imazeki I | 2005 | Autoimmunity2005，38，5： | 1 |
| 16 | Expression of p53 and p21^WAF1/CIP1 proteins in gastric and esophageal cancers:comparison with mutations of the p53 gene 显示文摘 | Sets T Imazeki F Yokosuka O | 1998 | Dig Dis Sci1998，43，3： | 1 |
| 17 | Aortic valve operations through an upper partialsternotomy显示文摘 | Kiyama H Imazeki T Irie Y | 1999 | Kyobu Geka1999，52，： | 1 |
| 18 | Analysis of the com- plete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocel!ular carcinoma 显示文摘 | Zhang KY Imazeki F Fukai K | 2007 | Cancer Sci2007，98，12： | 1 |
| 19 | Activation of a sys- tem A amino acid transporter, ATA1/SLC38A1 in human hepa- tocellular carcinoma and preneoplastic liver tissues显示文摘 | KONDOH N IMAZEKI N ARAI M | 2007 | Int J On- col2007，31，1： | 1 |
| 20 | Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients 显示文摘 | Imazeki F Yokosuka O Fukai K | 2008 | Liver Int2008，28，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员